A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)
Phase of Trial: Phase III
Latest Information Update: 02 Oct 2019
Price : $35 *
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome
- Focus Adverse reactions
- Acronyms TELEPATH
- Sponsors Lexicon Pharmaceuticals
- 02 Oct 2019 According to a Lexicon Pharmaceuticals media release, data will be presented at he upcoming North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium.
- 12 Mar 2019 Status changed from active, no longer recruiting to completed.
- 28 Feb 2019 According to a Lexicon Pharmaceuticals media release, the data from this study will be present at the 16th Annual European Neuroendocrine Tumor Society Conference (Mar 2019).